A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT02205528

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02205528
Other papers using this trial's data
  • The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Cell metabolism, 2017-08-01 DOI, PubMed 28768173

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02205528. Randomized; double masking; primary purpose treatment. Start 2014-08-18 (actual); primary completion 2015-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Condition
Diabetes
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
Liraglutide
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo
Intervention (Drug)
NNC0090-2746
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02205528
Content hash
2d38d2167d644acf8169ec36961e4be77ce71556b57a1e1a153245da7ac8fad4